Von Willebrand Factor–Targeting Thrombolysis to Overcome Tissue Plasminogen Activator Resistance In Vivo

Coen Maas, Ph.D.
University Medical Center Utrecht, Utrecht University
Utrecht, the Netherlands

Recombinant human tissue plasminogen activator (rh-tPA) is effective in <33% of patients after Acute Ischemic Stroke and is dependent on fibrin to initiate thrombolysis. Coen Maas, Ph.D., will discuss the presentation of mouse models with Microlyse, comparing rh-tPA that are either fibrin- or von Willebrand factor–dependent. Microlyse proves to be effective in both models in comparison to rh-tPA, which only reduces ischemic injury in a fibrin-dependent AIS model.

Previous Article Activation of the Plasma Contact System Triggers the Fat Embolism Syndrome
Next Article FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics and Efficacy